Page last updated: 2024-10-19

niacinamide and Diffuse Lymphocytic Lymphoma, Poorly-Differentiated

niacinamide has been researched along with Diffuse Lymphocytic Lymphoma, Poorly-Differentiated in 2 studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Research Excerpts

ExcerptRelevanceReference
"Sorafenib signaling was characterized by quantitative PCR, Western blotting, immunofluorescence, and protein immunoprecipitation."1.39Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma. ( Campo, E; Colomer, D; López-Guerra, M; Montraveta, A; Navarro, A; Pérez-Galán, P; Rosich, L; Roué, G; Saborit-Villarroya, I; Xargay-Torrent, S, 2013)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tarantelli, C1
Zhang, L1
Curti, E1
Gaudio, E1
Spriano, F1
Priebe, V1
Cascione, L1
Arribas, AJ1
Zucca, E1
Rossi, D1
Stathis, A1
Bertoni, F1
Xargay-Torrent, S1
López-Guerra, M1
Montraveta, A1
Saborit-Villarroya, I1
Rosich, L1
Navarro, A1
Pérez-Galán, P1
Roué, G1
Campo, E1
Colomer, D1

Other Studies

2 other studies available for niacinamide and Diffuse Lymphocytic Lymphoma, Poorly-Differentiated

ArticleYear
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.
    Haematologica, 2019, Volume: 104, Issue:7

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Bridge

2019
Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Feb-01, Volume: 19, Issue:3

    Topics: Actins; Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Movement; Chemok

2013